Evercore ISI Group analyst Cory Kasimov initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $113.
Evercore ISI Group Initiates Coverage On Biomarin Pharmaceutical With Outperform Rating, Announces Price Target of $113
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.